Table 3. Stratified analysis of overall and disease-free survival in TCGA samples.
| Characteristics | Overall survival | Disease-free survival | |||||
| High-risk / low-risk | HR (95% CI) | P value | High-risk / low-risk | HR (95% CI) | P value | ||
| Overall | 154/173 | 1.905 (1.248-2.910) | 0.0023* | 164/170 | 1.811 (1.329-2.466) | <0.0001* | |
| TNM stage | |||||||
| Stage I | 68/94 | 2.502 (1.295-4.835) | 0.0049* | 63/95 | 1.643 (0.9616-2.806) | 0.0509 | |
| Stage II | 36/38 | 1.383 (0.5167-3.700) | 0.5161 | 39/37 | 1.098 (0.5908-2.041) | 0.7632 | |
| Stage III | 38/26 | 2.263 (0.9245-5.539) | 0.0524 | 49/25 | 1.714 (0.9881-2.972) | 0.0592 | |
| Hepatitis | |||||||
| HBV | 44/50 | 3.622 (1.398-9.384) | 0.015* | 44/48 | 1.736 (0.9153-3.294) | 0.0873 | |
| HCV | 25/29 | 2.661 (0.8091-8.750) | 0.0644 | 23/28 | 1.263 (0.5953-2.682) | 0.5234 | |
| Non-hepatitis | 81/84 | 1.643 (0.9681-2.790) | 0.0539 | 90/84 | 2.157 (1.421-3.276) | 0.0002* | |
| Alcohol consumption | |||||||
| Yes | 40/54 | 2.235 (0.8735-5.719) | 0.0464* | 49/58 | 3.069 (1.736-5.426) | <0.0001* | |
| No | 110/109 | 0.807 (1.107-2.951) | 0.0188* | 108/102 | 1.429 (0.9693-2.105) | 0.0691 | |
| Gender | |||||||
| Male | 94/123 | 2.192 (1.243-3.863) | 0.0041* | 103/124 | 1.920 (1.304-2.826) | 0.0003* | |
| Female | 60/50 | 1.420 (0.7451-2.704) | 0.2847 | 61/46 | 1.711 (1.008-2.903) | 0.048* | |
| Age | |||||||
| ≤ 50 | 32/32 | 1.553 (0.4715-5.112) | 0.4636 | 38/30 | 1.765 (0.8905-2.497) | 0.0972 | |
| > 50 | 122/141 | 1.828 (1.165-2.868) | 0.0075* | 126/140 | 1.808 (1.278-2.558) | 0.0004* | |
| Cirrhosis | |||||||
| Yes | 34/42 | 3.445 (1.244-9.539) | 0.0237* | 33/42 | 0.9595 (0.522-1.764) | 0.8938 | |
| No | 51/77 | 1.323 (0.7002-2.500) | 0.3701 | 52/74 | 1.866 (1.114-3.125) | 0.0114* | |
| Albumin (g/dl) | |||||||
| ≤ 3.5 | 44/38 | 2.379 (1.030-5.495) | 0.061 | 41/36 | 1.203 (0.6193-2.337) | 0.5811 | |
| > 3.5 | 87/117 | 1.911 (1.102-3.312) | 0.0139* | 82/116 | 1.784 (1.183-2.691) | 0.0028* | |
| Creatinine(mg/dl) | |||||||
| < 1.1 | 87/108 | 1.888 (1.102-3.234) | 0.0171* | 81/105 | 1.665 (1.097-2.529) | 0.0113* | |
| ≥ 1.1 | 47/48 | 2.148 (0.9684-4.765) | 0.0507 | 44/45 | 1.428 (0.7646-2.668) | 0.2451 | |
| Alpha-fetoprotein(ng/ml) | |||||||
| ≤ 300 | 79/125 | 2.379 (1.334-4.243) | 0.0011* | 76/121 | 1.770 (1.147-2.731) | 0.0044* | |
| > 300 | 45/18 | 2.148 (0.7583-6.082) | 0.2203 | 41/17 | 1.425 (0.665-3.054) | 0.3896 | |
| Platelet(×109/L) | |||||||
| ≤ 300 | 101/120 | 2.421 (1.413-4.147) | 0.0013* | 95/119 | 1.527 (1.016-2.295) | 0.0337* | |
| > 300 | 34/38 | 1.338 (0.5988-2.988) | 0.4481 | 31/34 | 1.772 (0.9258-3.391) | 0.0671 | |
| Race | |||||||
| Asian | 65/63 | 4.354 (1.719-11.03) | 0.0041* | 83/65 | 2.046 (1.270-3.297) | 0.0034* | |
| White | 76/95 | 1.612 (0.9556-2.720) | 0.0623 | 69/91 | 1.901 (1.234-2.928) | 0.0015* | |
| BMIa | |||||||
| < 25 | 78/71 | 2.331 (1.201-4.523) | 0.0175* | 93/71 | 1.472 (0.9494-2.281) | 0.0855 | |
| ≥ 25 | 62/91 | 1.858 (0.9573-3.608) | 0.0454* | 56/87 | 2.549 (1.546-4.204) | <0.0001* | |
| Family history | |||||||
| Yes | 52/57 | 1.723 (0.9518-3.118) | 0.0669 | 85/91 | 1.543 (0.8052-2.957) | 0.1744 | |
| No | 48/52 | 1.882 (1.073-3.301) | 0.0214* | 101/90 | 1.639 (1.099-2.446) | 0.0135* | |
| ECOGb | |||||||
| =0 | 63/95 | 2.958 (1.476-5.931) | 0.002* | 59/93 | 1.463 (0.889-2.408) | 0.1159 | |
| >0 | 47/52 | 1.454 (0.6708-3.150) | 0.3143 | 62/52 | 2.165 (1.353-3.463) | 0.001* | |
| Histological grade | |||||||
| G1/2 | 73/127 | 1.445 (0.805-2.596) | 0.1908 | 82/126 | 1.936 (1.256-2.983) | 0.0008* | |
| G3/4 | 77/45 | 3.357 (1.698-6.636) | 0.0042* | 78/43 | 1.684 (1.033-2.747) | 0.0457* | |
Abbreviations: HR, hazard ratio; 95% CI, 95% confidence interval.
*: Statistically significant;
a: body mass index;
b: Eastern Cooperative Oncology Group.